Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis (SCRIPT-LGTB)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04528277 |
|
Recruitment Status :
Not yet recruiting
First Posted : August 27, 2020
Last Update Posted : August 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Infertility, Female Recurrent Implantation Failure Genital Tuberculoses, Female Genital Tuberculosis, Latent | Drug: rifapentine plus isoniazid | Phase 3 |
The prevalence of latent genital tuberculosis (LGTB) is relatively high in women with infertility and recurrent pregnancy loss. Whether preventive treatment of latent tuberculosis infection (LTBI) can improve the fertility outcome in women with recurrent implantation failure (RIF) remains to be explored.
This is a prospective interventional cohort study.The main purpose of this study is to compare the fertility outcome between 1-month regimen of three times weekly rifapentine plus isoniazid and no treatment in RIF patients with LGTB and RIF patients without LGTB. The study will also assess the safety and tolerability and the efficacy of the preventive treatment regimen in prevention of the incidence of active female genital tuberculosis (FGTB).
A total of 1050 participants will be recruited for screening of LGTB. The endometrial tuberculosis (TB) polymerase chain reaction (PCR) test will be employed for the diagnosis of LGTB. Eligible participants with negative TB PCR results will be assigned to the non-LGTB group, while those with positive TB PCR results will be assigned to the LGTB group. The LGTB group will be further assigned, according to their will to receive preventive treatment of tuberculosis, to one of the following groups: the LGTB treatment group and the LGTB no treatment group.
The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine plus isoniazid, and the in vitro fertilization (IVF)/ intra cytoplasmic sperm injection (ICSI) cycle can be started after 1 month post the completion of the treatment regimen. Adverse events and side effects will be monitored at a 2-week interval during the preventive treatment and followed up once more at 4 weeks post the end of treatment. The LGTB no treatment group and the non-LGTB group will start the IVF/ICSI cycle directly after enrollment without taking any medication related to preventive treatment of tuberculosis.
Eligible participants will be followed up until the end of an IVF/ ICSI cycle or pregnancy. Fertility outcomes of both groups will be recorded and compared. Secondary outcomes, including the incidence of adverse events, the adhesion of treatment and the incidence of LGTB and FGTB, ovarian reserve, embryo quality, history of infertility and tuberculosis will also be recorded and compared.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1050 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Role of Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis in Women With Recurrent Implantation Failure: A Prospective Interventional Cohort Study |
| Estimated Study Start Date : | September 1, 2020 |
| Estimated Primary Completion Date : | September 1, 2021 |
| Estimated Study Completion Date : | September 1, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: LGTB treatment group
The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw).
|
Drug: rifapentine plus isoniazid
receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po) |
|
No Intervention: LGTB no treatment group
The LGTB no treatment group will not take any medication related to preventive treatment of tuberculosis.
|
|
|
No Intervention: non-LGTB group
The non-LGTB group will not take any medication related to preventive treatment of tuberculosis.
|
- Clinical pregnancy rates [ Time Frame: 6 weeks after completion of an IVF/ICSI cycle ]Clinical pregnancy was defined as the presence of at least one gestational sac on ultrasound at 6 weeks.
- Ongoing Pregnancy Rate [ Time Frame: 10 weeks after completion of an IVF/ICSI cycle ]Ongoing pregnancy was the presence of at least one foetus with heart pulsation on ultrasound beyond 10 weeks.
- Miscarriage rate [ Time Frame: 22 weeks after completion of an IVF/ICSI cycle ]The number of miscarriages before 22 weeks divided by the number of participants with positive pregnancy test.
- Implantation rate [ Time Frame: 6 weeks after completion of an IVF/ICSI cycle ]The number of gestational sacs seen on scanning divided by the number of embryos replaced.
- Incidence of LGTB [ Time Frame: 4 weeks after enrollment ]The number of participants diagnosed with LGTB devided by the number of participants screened for LGTB.
- Incidence of FGTB [ Time Frame: 2 years ]The number of participants developed FGTB during treatment or follow-up devided by the number of participants in the LGTB treatment group.
- Incidence of grade 3 or greater adverse events [ Time Frame: 20 weeks after preventive treatment initiated ]The number of participants reported grade 3 or greater adverse events during treatment or follow-up devided by the number of participants in the LGTB treatment group.
- Completion rate of preventive treatment [ Time Frame: 20 weeks after preventive treatment initiated ]11 or 12 doses of the 1-month preventive treatment regimen of three times weekly rifapentine plus isoniazid taken within 16 weeks after treatment initiated will be regarded as completion of preventive treatment. The number of participants completed treatment devided by the number of participants initiated the preventive treatment.
- Discontinuation of treatment [ Time Frame: 20 weeks after preventive treatment initiated ]The number of participants discontinued treatment devided by the number of participants in the LGTB treatment group.
- Discontinuation of treatment due to side effect of study drugs [ Time Frame: 20 weeks after preventive treatment initiated ]The number of participants discontinued treatment due to side effect of study drugs devided by the number of participants in the LGTB treatment group.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women aged 25-40 years old
- Infertile women failed to achieve clinical pregnancy after 4 good quality embryo transfers, with at least 3 fresh or frozen IVF cycles
- Intended to undergo IVF/ICSI
- Ultrasonography or hysterosalpingogram showed a normal uterus cavity, and the thickness of the endometrium was ≥8mm before implantation during last IVF/ICSI cycle
- Patients who voluntarily signed the informed consent and agreed to be followed up as required by the study protocol
Exclusion Criteria:
- Use of donor eggs/sperm
- An abnormal uterine cavity shown on hysterosalpingogram or hysteroscopy
- Proven tubal infertility
- Proven preimplantation genetic abnormality
- Proven active tuberculosis
- Treated for active tuberculosis or used preventive treatment for LTBI within 2 years
- Being allergic or intolerant of any study drug
- HIV antibody positive and AIDS patients
- Patients with impaired liver function: hepatic encephalopathy, ascites; total bilirubin is more than 2 times higher than the upper limit of normal; alanine transaminase (ALT) or aspartate aminotransferase (AST) is more than 5 times the upper limit of normal
- Patients with diabetes mellitus
- Critically ill patients, and according to the judgment of the research physician, it is impossible to survive for more than 16 weeks
- Currently participating in another drug clinical trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04528277
| Contact: Qiaoling Ruan, Dr. | 021-52887946 | qlruan07@fudan.edu.cn | |
| Contact: Xiaoming Teng, Dr. | 021-54035206 | tengxiaoming@51mch.com |
| China, Shanghai | |
| Shanghai First Maternity and Infant Hospital | |
| Shanghai, Shanghai, China, 200051 | |
| Contact: Xiaoming Teng, Dr. 021-54035206 tengxiaoming@51mch.com | |
| Principal Investigator: Xiaoming Teng, Dr. | |
| Sub-Investigator: Zhiqin Chen, Dr. | |
| Responsible Party: | Wen-hong Zhang, director of department of infectious diseases, Huashan Hospital |
| ClinicalTrials.gov Identifier: | NCT04528277 |
| Other Study ID Numbers: |
KS20232 |
| First Posted: | August 27, 2020 Key Record Dates |
| Last Update Posted: | August 27, 2020 |
| Last Verified: | August 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Tuberculosis Latent Tuberculosis Tuberculosis, Female Genital Infertility Infertility, Female Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections Latent Infection Tuberculosis, Urogenital |
Isoniazid Rifapentine Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Fatty Acid Synthesis Inhibitors Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Antibiotics, Antitubercular Leprostatic Agents |